Want to join the conversation?
In 1Q16, $LRCX's non-GAAP gross margins came in at 46.5% which was at the high-end of its guidance; the strength was driven by better mix and stronger manufacturing absorption. OpEx came in at $364MM which resulted in operating income of 23.8%. Further, non-GAAP earnings per share of $1.82 ended up above the high-end of its guidance.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.